Eupraxia Pharmaceuticals Inc.
NASDAQTotal Valuation
Eupraxia Pharmaceuticals Inc. carries a market capitalization of 218.29M, placing it among publicly traded companies globally. Its enterprise value stands at 326.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 218.29M |
| Enterprise Value | 326.12M |
Share Statistics
Eupraxia Pharmaceuticals Inc. currently has 61.81M shares outstanding.
| Shares Outstanding | 61.81M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 5.94 |
| P/TBV Ratio | 4.09 |
| P/FCF Ratio | -13.61 |
| P/OCF Ratio | -13.30 |
Financial Position
Eupraxia Pharmaceuticals Inc. maintains a current ratio of 19.30, meaning it holds 19.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 19.30 |
| Quick Ratio | 18.95 |
| Debt / Equity | 1.47 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -50.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 30,202.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Eupraxia Pharmaceuticals Inc.'s stock has gained approximately 20.74074% over the past 52 weeks. The 50-day moving average sits at 6.83, while the 200-day moving average is 6.95.
| Beta (5Y) | N/A |
| 52-Week Price Change | 20.74074% |
| 50-Day Moving Average | 6.83 |
| 200-Day Moving Average | 6.95 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -46.99M, while operating income came in at -47.27M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -47.27M |
| Pretax Income | -44.46M |
| Net Income | -44.47M |
| EBITDA | -46.99M |
| EBIT | -47.27M |
| Earnings Per Share (EPS) | -1.03 |
Balance Sheet
Eupraxia Pharmaceuticals Inc. holds 138.88M in cash and equivalents against 2.01M in total debt, resulting in a net debt position of -58.50M. Total book value stands at 73.26M, with working capital of 134.76M providing operational flexibility.
| Cash & Cash Equivalents | 138.88M |
| Total Debt | 2.01M |
| Net Debt | -58.50M |
| Equity (Book Value) | 73.26M |
| Book Value Per Share | 1.70 |
| Working Capital | 134.76M |
Cash Flow
Eupraxia Pharmaceuticals Inc. produced -32.70M in operating cash flow over the past twelve months. After subtracting -746,856.00 in capital expenditures, free cash flow totaled -33.44M - equivalent to -0.77 per share.
| Operating Cash Flow | -32.70M |
| Capital Expenditures | -746,856.00 |
| Free Cash Flow | -33.44M |
| FCF Per Share | -0.77 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -33.16 |
| FCF Yield | -7.35 |
Scores
Eupraxia Pharmaceuticals Inc. posts an Altman Z-Score of 26.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 26.75 |